A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese Subjects
A Phase 1 Open-label, Non-randomized, Single Ascending Dose Escalation Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of A Ralinepag Extended Release (XR) Tablet Formulation In Healthy Chinese Subjects.
100 Clinical Results associated with Everstar Medicines Shanghai Ltd.
0 Patents (Medical) associated with Everstar Medicines Shanghai Ltd.
100 Deals associated with Everstar Medicines Shanghai Ltd.
100 Translational Medicine associated with Everstar Medicines Shanghai Ltd.